Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.

ABSTRACT:

Background

Decisions about which subgroup of chronic hepatitis C (CHC) patients should be treated with direct acting anti-viral agents (DAAs) have economic importance due to high drug prices. Treat-all DAA strategies for CHC have gained acceptance despite high drug acquisition costs. However, there are also costs associated with the surveillance of CHC to determine a subgroup of patients with significant impairment. The aim of this systematic review was to describe the modelling methods used and summarise results in cost-effectiveness analyses (CEAs) of both CHC treatment with DAAs and surveillance of liver disease.

Methods

Electronic databases including Embase and Medline were searched from inception to May 2015. Eligible studies included models predicting costs and/or outc

SUBMITTER: Castro R 

PROVIDER: S-EPMC5998601 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature